Compare Cronos Group Inc (CRON) vs Ingersoll Rand (IR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Ingersoll Rand — how do they compare? Cronos Group Inc trades at $3.3 (market cap $1.18B), while Ingersoll Rand trades at $71.63 (market cap $27.90B). The key difference: Ingersoll Rand is far larger — about 23.6× Cronos Group Inc's market cap, and Ingersoll Rand pays a 0.11% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | IR | |
|---|---|---|
Market Cap | $1.18B | $27.90B |
Volume | 581,592 | 5,665,729 |
Sector | Health | Industrials |
52-Week High | $3.55 | $98.76 |
52-Week Low | $2.30 | $68.54 |
Typical Hold Time | 22 Days | — |
Enterprise Value | $386.30M | $31.56B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.29, up 1.7% with a bullish technical signal. Recent earnings beat expectations, with Q2 2026 EPS of $0.09 vs. $0.01 expected. Revenue grew to $147 million in 2025, though net income was negative. The company holds $827 million cash with no debt, supporting expansion. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook is cautiously optimistic due to strong cash position and international growth, but profitability risks and regulatory uncertainty pose challenges. The stock offers value with a P/E of 16.87, yet high EV/EBITDA of 42.85 signals premium valuation relative to earnings power.
Ingersoll Rand (IR) trades at $71.91, down 0.31% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.86, beating estimates, and raised full-year revenue guidance. Financials show solid profitability with a 12.08% net margin and $581.4M net income for 2025. Recent news highlights investor conferences and the acquisition of Lone Star Blower, expanding industrial capabilities.
Outlook is supported by earnings beats and raised guidance, but high P/E of 29.71 poses valuation risk. Analyst consensus is bullish with a $90.60 price target, though technical weakness and margin compression from Q2 warrant caution. Key risks include execution of growth initiatives and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →
